泓博医药
(301230)
| 流通市值:38.42亿 | | | 总市值:42.72亿 |
| 流通股本:1.63亿 | | | 总股本:1.81亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 550,795,701.14 | 364,406,306.14 | 172,285,876.53 | 688,350,863.65 |
| 营业总成本 | 534,249,866.2 | 348,643,419.8 | 159,696,084.51 | 655,923,295.42 |
| 其他经营收益 | | | | |
| 营业利润 | 29,923,008.97 | 31,471,609.65 | 26,398,618.34 | 28,621,094.95 |
| 利润总额 | 28,528,704.49 | 30,134,483.58 | 25,984,761.82 | 28,316,885.7 |
| 净利润 | 29,050,680.01 | 28,729,363.74 | 23,779,249.5 | 34,294,767.32 |
| 每股收益 | | | | |
| 其他综合收益 | -42,621.55 | -3,995.55 | -114,466.4 | -17,625.94 |
| 综合收益总额 | 29,008,058.46 | 28,725,368.19 | 23,664,783.1 | 34,277,141.38 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 542,941,183.9 | 565,319,888.89 | 578,133,505.52 | 582,095,905.67 |
| 非流动资产: | | | | |
| 非流动资产合计 | 743,720,013.72 | 737,109,783.65 | 737,709,880.14 | 732,003,270.12 |
| 资产总计 | 1,286,661,197.62 | 1,302,429,672.54 | 1,315,843,385.66 | 1,314,099,175.79 |
| 流动负债: | | | | |
| 流动负债合计 | 155,047,722.4 | 167,799,625.09 | 153,754,515.99 | 172,212,045.67 |
| 非流动负债: | | | | |
| 非流动负债合计 | 117,491,294.6 | 122,164,168.4 | 132,137,306.02 | 137,657,022.3 |
| 负债合计 | 272,539,017 | 289,963,793.49 | 285,891,822.01 | 309,869,067.97 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,014,122,180.62 | 1,012,465,879.05 | 1,029,951,563.65 | 1,004,230,107.82 |
| 股东权益合计 | 1,014,122,180.62 | 1,012,465,879.05 | 1,029,951,563.65 | 1,004,230,107.82 |
| 负债和股东权益合计 | 1,286,661,197.62 | 1,302,429,672.54 | 1,315,843,385.66 | 1,314,099,175.79 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 537,889,932.47 | 346,125,903.8 | 176,532,345.46 | 604,871,381.42 |
| 经营活动现金流出小计 | 439,930,348.9 | 274,111,094.43 | 146,784,870.1 | 469,359,439.29 |
| 经营活动产生的现金流量净额 | 97,959,583.57 | 72,014,809.37 | 29,747,475.36 | 135,511,942.13 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 418,028,744.95 | 257,573,696.95 | 167,625,628.12 | 23,226,822.53 |
| 投资活动现金流出小计 | 395,390,973.65 | 262,425,629.61 | 172,118,035.78 | 66,616,262.01 |
| 投资活动产生的现金流量净额 | 22,637,771.3 | -4,851,932.66 | -4,492,407.66 | -43,389,439.48 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 13,649,800 | 9,399,800 | - | 25,664,755.58 |
| 筹资活动现金流出小计 | 74,791,901.54 | 39,928,726.76 | 19,808,244.53 | 105,533,456.16 |
| 筹资活动产生的现金流量净额 | -61,142,101.54 | -30,528,926.76 | -19,808,244.53 | -79,868,700.58 |
| 汇率变动对现金及现金等价物的影响 | -4,983,315.54 | -2,973,470.67 | -1,553,587.61 | 1,815,915.65 |
| 现金及现金等价物净增加额 | 54,471,937.79 | 33,660,479.28 | 3,893,235.56 | 14,069,717.72 |
| 期末现金及现金等价物余额 | 107,290,602.68 | 86,479,144.17 | 56,711,900.45 | 52,818,664.89 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 33,660,479.28 | - | 14,069,717.72 |